The income statement and balance sheet and the consolidated accounts and the consolidated balance sheet, disposition of the Company's profit or loss and discharge from liability

The general meeting resolved to adopt the income statement and balance sheet as well as the consolidated accounts and the consolidated balance sheet for the fiscal year 2025, as presented in the annual report. Furthermore, the meeting resolved, in accordance with the board of directors' proposal, that no dividend shall be paid and that the amount at the disposal of the meeting shall be carried forward to a new account.

The meeting also resolved to grant discharge from liability to the board members, the chairman of the board and the chief executive officer for their administration of the Company's affairs during the previous fiscal year.

Determination of fees for the board of directors and auditors

The general meeting resolved that board fees shall be paid to non-employee board members at a rate of three (3) price base amounts to the chairman of the board and two (2) price base amounts each to the other ordinary board members. It was further resolved that remuneration to members of the nomination committee shall be paid at a rate of one half (0.5) of a price base amount each, and that Enorama Pharma shall cover any personal expenses that may arise in connection with the performance of duties on the board, committees or the nomination committee.

The general meeting further resolved that no remuneration shall be paid to members of the board or the nomination committee who are employees of Enorama Pharma or nominated by shareholders holding more than ten (10) per cent of the Company's total outstanding shares at the time of the annual general meeting. The meeting resolved that remuneration to the Company's auditor shall be paid in accordance with an approved invoice in line with customary charging principles.

Election of the board of directors and auditors

The general meeting resolved that Enorama Pharma's board of directors shall consist of seven (7) ordinary members without deputies and that the Company shall have one (1) registered accounting firm as auditor.

The general meeting resolved to re-elect Fredrik Olsson, Tanu Tandan, Mikael Åbom, Ara Abrahamian, Yugnesh Kumar Agrawal, Rajesh Kumar and Richard Svensson as ordinary board members. Ara Abrahamian was re-elected as chairman of the board.

The general meeting also resolved to re-elect the Company's auditor, Ernst & Young AB, which has announced that Erik Mauritzson will be the auditor in charge.

Authorisation for the board of directors to resolve on issue of shares, convertibles and/or warrants

The general meeting resolved to authorise the board to, on one or more occasions, during the period until the next annual general meeting, resolve to increase the Enorama Pharma's share capital. The increase in the share capital may take place through a new issue of shares and/or convertibles and/or warrants entitling the holder to convert into or subscribe for new shares. The board of directors shall have the right to resolve on such an issue with deviation from shareholders' preferential rights and/or with provisions for payment in cash or by way of a contribution in kind, set-off or otherwise on terms in accordance with Chapter 2, Section 5, second paragraph, points 1-3 and 5 of the Companies Act (2005:551).

CONTACT

Enorama Pharma AB (publ)

Bengt Jönsson, acting CEO

info@enorama.se

Strandvägen 7A, 114 51 Stockholm

www.enorama.se

Enorama Pharma AB is listed on the Nasdaq First North Growth Market.

The Company's Certified Adviser is Tapper Partners AB, +46 (0)70 44 010 98, ca@tapperpartners.se.

ABOUT ENORAMA PHARMA

Enorama Pharma's vision is to be a leading global manufacturer and supplier of consumer-friendly, oral nicotine products. The Company intends to expand through product and brand development and by establishing strategically important partnerships. For more information, visit www.enorama.se.